2-(2-羧乙基硫烷基硫代羰基硫烷基)丙酸 | 870451-09-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 2-(2-羧乙基硫烷基硫代羰基硫烷基)丙酸
• 英文名称: 2-(2-carboxyethylsulfanylthiocarbonylsulfanyl)propionic acid
• 英文别名: 2-(2-carboxyethylsulfanylcarbothioylsulfanyl)propanoic acid
• CAS: 870451-09-5
• 化学式: C₇H₁₀O₄S₃
• 分子量: 254.352
• InChiKey: IKWGMGMZWODWEO-UHFFFAOYSA-N

物化性质

• 熔点：
  120-125 °C
• 沸点：
  528.8±43.0 °C(Predicted)
• 密度：
  1.526±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  14
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  157
• 氢给体数：
  2
• 氢受体数：
  7

安全信息

• WGK Germany：
  3
• 储存条件：
  存放在室温下，密封保存，并确保环境干燥。

反应信息

• 作为反应物：
  描述：

  2-(2-羧乙基硫烷基硫代羰基硫烷基)丙酸 、 2-丙炔-1-醇 在 4-二甲氨基吡啶 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 反应 20.0h， 以46%的产率得到(propynyl 2-propanoate)yl (propynyl 3-propanoate)yl trithiocarbonate
  参考文献：
  名称：

  Hierarchical Assembly of Branched Supramolecular Polymers from (Cyclic Peptide)–Polymer Conjugates

  摘要：

  We report the synthesis and assembly of (N-methylated cyclic peptide)polymer conjugates for which the cyclic peptide is attached to either the alpha- or both alpha- and omega- end groups of a polymer. A combination of chromatographic, spectroscopic, and scattering techniques reveals that the assembly of the conjugates follows a two-level hierarchy, initially driven by H-bond formation between two N-methylated cyclic peptides, followed by unspecific, noncovalent aggregation of this peptide into small domains that behave as branching points and lead to the formation of branched supramolecular polymers.

  DOI：

  10.1021/bm501062d
• 作为产物：
  描述：

  二硫化碳 、 2-溴丙酸 、 3-巯基丙酸 在 sodium hydroxide 作用下， 以 水 为溶剂， 反应 0.5h， 生成 2-(2-羧乙基硫烷基硫代羰基硫烷基)丙酸
  参考文献：
  名称：

  Thermo-responsive shell cross-linked PMMA-b-P(NIPAAm-co-NAS) micelles for drug delivery

  摘要：

  Thermo-responsive amphiphilic poly(methyl methacrylate)-b-poly(N-isopropylacrylamide-co-N-acryloxysuccinimide) (PMMA-b-P(NIPAAm-co-NAS)) block copolymer was synthesized by successive RAFT polymerizations. The uncross-linked micelles were facilely prepared by directly dissolving the block copolymer in an aqueous medium, and the shell cross-linked (SCL) micelles were further fabricated by the addition of ethylenediamine as a di-functional cross-linker into the micellar solution. Optical absorption measurements showed that the LCST of uncross-linked and cross-linked micelles was 31.0 degrees C and 40.8 degrees C, respectively. Transmission electron microscopy (TEM) showed that both uncross-linked and cross-linked micelles exhibited well-defined spherical shape in aqueous phase at room temperature, while the SCL micelles were able to retain the spherical shape with relatively smaller dimension even at 40 degrees C due to the cross-linked structure. In vitro drug release study demonstrated a slower and more sustained drug release behavior from the SCL micelles at high temperature as compared with the release profile of uncross-linked micelles, indicating the great potential of SCL micelles developed herein as novel smart carriers for controlled drug release. (c) 2011 Elsevier B.V. All rights reserved.

  DOI：

  10.1016/j.ijpharm.2011.08.038

文献信息

• Polymeric prodrugs and subcutaneous and/or intramuscular administration thereof
  申请人：CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

  公开号：US20200353090A1

  公开（公告）日：2020-11-12

  The invention relates to new prodrugs of active molecules. These prodrugs allow, in particular, the subcutaneous or intramuscular administration of active molecules of which the subcutaneous or intramuscular administration is problematic or impossible, in particular because of the toxicity at the injection site. The prodrugs according to the invention comprise an active ingredient, covalently linked with a polymer chain, preferably a hydrophilic and/or thermosensitive polymer chain. The invention relates, in particular, to polymeric prodrugs comprising a polymer chain formed at least in part by acrylamide monomer or one of its derivatives, the polymer comprising a proximal part and a terminal part; a first pharmaceutically active molecule covalently coupled to the proximal part of the polymer; possibly a second pharmaceutically active molecule covalently coupled to the terminal part of the polymer.

  该发明涉及新型活性分子的前药。这些前药允许特别是将活性分子皮下或肌肉内注射，而这些活性分子的皮下或肌肉内注射由于在注射部位的毒性而具有问题或不可能，特别是由于在注射部位的毒性。根据本发明的前药包括一种活性成分，与一根聚合物链共价连接，优选为一种亲水性和/或热敏感性聚合物链。该发明特别涉及包括由丙烯酰胺单体或其衍生物之一至少部分形成的聚合物链的聚合物前药，该聚合物包括一个近端部分和一个末端部分；第一种药用活性分子共价结合到聚合物的近端部分；可能第二种药用活性分子共价结合到聚合物的末端部分。
• AMPHIPHILIC MACROMOLECULAR EMULSIFIER WITH SWITCHABLE SURFACE ACTIVITY AND USE THEREOF IN PREPARATION OF POLYMER LATEX
  申请人：ZHEJIANG UNIVERSITY

  公开号：US20140316049A1

  公开（公告）日：2014-10-23

  A macromolecular emulsifier with switchable surface activity, and use thereof for preparation of polymer latex is disclosed. By using the macromolecular emulsifier with switchable surface activity as an emulsifier, a reversibly coagulable and re-dispersible polymer latex can be prepared by emulsion polymerization. The polymer latex can achieve the coagulation of latex particles by heating and aerating with nitrogen, air, inert gas and/or adding a small amount of alkali solution; the coagulated latex particles can be restored and re-dispersed into stable latex by aerating with carbon dioxide and/or adding a small amount of acid solution. The coagulation and re-dispersion process is reversible and is easy to control.

  本发明涉及一种具有可切换表面活性的高分子乳化剂，以及其用于制备聚合物乳液。通过使用具有可切换表面活性的高分子乳化剂作为乳化剂，可以通过乳液聚合制备可逆凝固和可再分散的聚合物乳液。该聚合物乳液可以通过加热和通入氮气、空气、惰性气体和/或添加少量碱溶液来实现乳胶颗粒的凝固；通过通入二氧化碳和/或添加少量酸溶液来恢复和重新分散凝固的乳胶颗粒为稳定的乳液。凝固和重新分散过程是可逆的，并且易于控制。
• Impact resistant cyclic phosphazenes
  申请人：INTERNATIONAL BUSINESS MACHINES CORPORATION

  公开号：US10544285B2

  公开（公告）日：2020-01-28

  An impact-modified composition and a method of making an impact-modified composition are provided. In an embodiment, the method includes reacting a phosphazene material with an acrylamide material to form a functionalized phosphazene material; initiating a polymerization reaction on a reaction mixture comprising the functionalized phosphazene material and one or more monomers to form an impact-modified phosphazene material; and adding the an impact-modified phosphazene material to a polymeric material.

  本发明提供了一种抗冲击改性组合物和一种抗冲击改性组合物的制造方法。在一个实施方案中，该方法包括：使磷化烯材料与丙烯酰胺材料反应，形成官能化磷化烯材料；在包含官能化磷化烯材料和一种或多种单体的反应混合物上引发聚合反应，形成抗冲改性磷化烯材料；以及将抗冲改性磷化烯材料添加到聚合材料中。
• Adhesive composition
  申请人：TOAGOSEI CO., LTD.

  公开号：US10982115B2

  公开（公告）日：2021-04-20

  An adhesive composition according to the present invention contains a polymerizable monomer (A) and a block copolymer (B) including a polymer block (a) which includes structural units derived from a styrene compound and from a maleimide compound, and an acrylic polymer block (b), in which the polymer block (a) and the acrylic polymer block (b) have a solubility parameter of 10.0 or more and 9.0 or more, respectively; the polymer block (a) contains the structural unit derived from a maleimide compound at a concentration from 30% by mass to 99% by mass with respect to the total mass of the polymer block (a); the polymer block (a) has a glass transition temperature of 150° C. or higher; and the polymer block (b) has a glass transition temperature of 20° C. or lower.

  根据本发明的一种粘合剂组合物含有可聚合单体（A）和嵌段共聚物（B），嵌段共聚物（B）包括聚合物嵌段（a），聚合物嵌段（a）包括衍生自苯乙烯化合物和衍生自马来酰亚胺化合物的结构单元，以及丙烯酸聚合物嵌段（b），其中聚合物嵌段（a）和丙烯酸聚合物嵌段（b）的溶解度参数分别为 10.聚合物嵌段（a）含有马来酰亚胺化合物衍生的结构单元，其浓度为聚合物嵌段（a）总质量的 30% 至 99%；聚合物嵌段（a）的玻璃化转变温度为 150 摄氏度或更高；聚合物嵌段（b）的玻璃化转变温度为 20 摄氏度或更低。
• Protein aggregation inhibitor
  申请人：OSAKA ORGANIC CHEMICAL INDUSTRY LTD.

  公开号：US10995160B2

  公开（公告）日：2021-05-04

  The present invention provides a protein aggregation inhibitor for use in preventing aggregation of a protein, which contains a terminal sulfanyl group-containing sulfobetaine polymer having a repeat unit derived from a sulfobetaine monomer represented by the formula (II), and a noble metal particle, and in which the terminal sulfanyl group-containing sulfobetaine polymer is chemisorbed on the noble metal particle by the sulfanyl group (the groups in the following formula are as defined in the DESCRIPTION).

  本发明提供了一种用于防止蛋白质聚集的蛋白质聚集抑制剂，该抑制剂含有含端硫基的磺基甜菜碱聚合物（其重复单元来源于由式（II）表示的磺基甜菜碱单体）和惰性金属颗粒，其中含端硫基的磺基甜菜碱聚合物通过硫基化学吸附在惰性金属颗粒上（下式中的基团如说明书中所定义）。